Arena Pharmaceutical (ARNA) 1.56 $ARNA Arena

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 7:43 PM

Arena Pharmaceutical (ARNA) 1.56 $ARNA

Arena Pharmaceutics Announces Formation of Beacon Discovery
PR Newswire - Thu Sep 01, 3:30PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the formation of Beacon Discovery Inc. ("Beacon"

, an independent, privately-held drug discovery incubator.
ARNA: 1.56 (+0.01)

Actelion (ALIOF) Uptravi Approved for PAH in Switzerland
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 7:29AM CDT
Actelion (ALIOF) announced that Uptravi was granted approval by Swissmedic for treatment of patients with pulmonary arterial hypertension (PAH).
ANIP: 61.42 (+1.68), ANIK: 47.94 (+0.70), ARNA: 1.56 (+0.01)

Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
PR Newswire - Mon Aug 15, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced that Vincent Aurentz will join its management team as Executive Vice President and Chief Business Officer, effective today. Mr. Aurentz will report to Amit Munshi, Arena's President and Chief Executive Officer.
ARNA: 1.56 (+0.01)

Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:19AM CDT
Arena (ARNA) continues to work on the advancement of its proprietary pipeline candidates.
HSKA: 52.76 (-1.81), CBM: 43.17 (+0.34), ANIP: 61.42 (+1.68), ARNA: 1.56 (+0.01)

Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon Aug 08, 3:01PM CDT
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today reported financial results for the second quarter ended June 30, 2016, and provided a corporate update.
ARNA: 1.56 (+0.01)

Biotech Stocks Technical Report -- Arena Pharma, BIND Therapeutics, Nektar Therapeutics, and Regeneron Pharma
PR Newswire - Wed Aug 03, 7:50AM CDT
Stock-Callers.com focus is on the Biotech arena which has had an impressive performance in the last few days. On Monday, August 01, 2016, stocks within the biotech space drove the NYSE Arca Biotechnology Index up by 2.4%. Today, we review Arena Pharmaceuticals Inc. (NASDAQ: ARNA), BIND Therapeutics Inc. (NASDAQ: BIND), Nektar Therapeutics (NASDAQ: NKTR), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BIND: 0.78 (-0.09), ARNA: 1.56 (+0.01), REGN: 393.40 (+0.85), NKTR: 18.11 (+0.26)

Arena Pharmaceuticals to Release Second Quarter 2016 Financial Results and Provide Corporate Update on Monday, August 8, 2016
PR Newswire - Mon Aug 01, 3:01PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its second quarter 2016 financial results and provide a corporate update on Monday, August 8, 2016, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community on Monday, August 8, 2016 at 4:30 p.m. ET to discuss the financial results and provide a corporate update.
ARNA: 1.56 (+0.01)

Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 2.45 (-0.15), ARNA: 1.56 (+0.01), EXEL: 11.35 (+0.20)

How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
PR Newswire - Thu Jun 23, 6:30AM CDT
The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. Stock-Callers.com assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:
VRTX: 94.75 (+0.24), XON: 25.29 (+0.05), ARNA: 1.56 (+0.01), REGN: 393.40 (+0.85)

Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name "Etrasimod" for its Drug Candidate APD334
PR Newswire - Mon Jun 13, 6:00AM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the United States Adopted Names (USAN) Council has approved the nonproprietary name etrasimod (pronounced Et-ras'-i-mod) for APD334, a selective oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in autoimmune diseases. Arena is currently studying etrasimod in a Phase 2 clinical trial for ulcerative colitis.
ARNA: 1.56 (+0.01)

Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.92 (-0.01), RTRX: 16.35 (+0.33), VVUS: 1.06 (unch), ARNA: 1.56 (+0.01)

Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:51AM CDT
As of late, it has definitely been a great time to be an investor in Arena Pharmaceuticals, Inc. (ARNA)
ARNA: 1.56 (+0.01)

Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Tue May 10, 7:27AM CDT
Sales of Arena's (ARNA) obesity treatment, Belviq, remain lackluster.
HSKA: 52.76 (-1.81), CBM: 43.17 (+0.34), ANIP: 61.42 (+1.68), ARNA: 1.56 (+0.01)

Arena Pharmaceuticals reports 1Q loss
Automated Insights - Mon May 09, 4:07PM CDT
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a loss of $21.5 million in its first quarter.
ARNA: 1.56 (+0.01)

Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has appointed Amit D. Munshi as President, Chief Executive Officer and interim principal financial officer, effective May 11, 2016. Mr. Munshi will also join Arena's Board of Directors following Arena's 2016 annual stockholders' meeting, which is scheduled for June 13, 2016.
ARNA: 1.56 (+0.01)

Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Mon May 09, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported financial results for the first quarter ended March 31, 2016, and provided a corporate update.
ARNA: 1.56 (+0.01)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.45 (+0.01), INO: 9.14 (-0.03), VVUS: 1.06 (unch), TEVA: 50.90 (+0.51), ARNA: 1.56 (+0.01), PBYI: 58.71 (-0.44)

Arena Pharmaceuticals to Host First Quarter 2016 Financial Results and Corporate Update Conference Call and Webcast on Monday, May 9
PR Newswire - Mon May 02, 3:05PM CDT
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Monday, May 9, 2016, to discuss first quarter 2016 financial results and provide a corporate update. Arena will issue a press release with its financial results after the NASDAQ Global Select Market closes that day.
ARNA: 1.56 (+0.01)

New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 17.14 (+0.29), ALIM: 1.55 (+0.02), ARES: 18.92 (+0.64), AXTA: 28.95 (+0.33), ARNA: 1.56 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Lawsuit Hits Desert Resort Management

Desert Resort Management in Labor Hot Seat Alright, here's a twist that might make your coffee spill—Desert Resort Management, Inc. is caught in a legal whirlwind in Riverside County. The heavy hitters at Blumenthal Nordrehaug Bhowmik De Blouw LLP have slapped a lawsuit right in their face, alleging some grimy labor practices. They're claiming that the company wasn't...

Celina Graves Joins Expanding GoLive Streamers Platform

Celina Graves Breaks New Ground on GoLive Streamers You'd think television capture all the talent buzz, but nope. Celina Graves, known from her semifinalist run on America's Got Talent, is diving into new waters by joining GoLive Streamers. She's stirring up the scene by making her performances more personal, stretching beyond the flatness of your typical TV appearance....

Accuray, Samsung Push Boundaries with Imaging Deal

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

J.P. Morgan, Thunes Partner for Global Payment Integration

You don't need a crystal ball to see J.P. Morgan's playing the long game by teaming up with Thunes. In this world, where cash is digital and the reach is global, it's all about speed and scale—brushing elbows with the right partners makes all the difference. Sometimes it's about knowing when to hitch your wagon to a reliable workhorse, especially when global commerce is...

Revamping Children's Radiotherapy: Leo Cancer Care's Vision

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Craig Hospital Expands: A Milestone for Rehab Care

A Bold Step Forward in Neurorehabilitation Over a September sky in Englewood, Colorado, a ceremonial beam rose, marking a major milestone for Craig Hospital. It's not just steel and concrete; it's hope and progress for many who've found themselves at the mercy of neurological injuries. Celebrating the 'topping out' of their expanded campus, Craig's latest step forward...

Elevest's Fund 70: High Hopes in Dallas Tower Deal

Aiming High in the Heart of Dallas Rolling the dice in downtown Dallas isn't for the faint-hearted, but Elevest Capital is strutting in with swagger. Their 70th fund acquisition—a 229-unit high-rise—is rocking the highest going-in cap rate the firm has ever snagged at 6.4%. Built in 2007 and lounging at a comfy 93% occupancy with zero concessions, this property sure...

AHN Healthcare@Home Celebrates Fourth Top Workplace Win

Four-Time Top Workplace Champ You want to talk consistency? Let's talk about AHN Healthcare@Home pulling in that Pittsburgh Top Workplace award four years running. It's no small feat, especially in the healthcare sector where employee burnout isn't just a buzzword—it's a daily challenge. How did a home health and hospice outfit like AHN land this honor? Well, it's all...

NUS Unveils eLuminator: A Leap for Robotics & Healthcare

Game-Changing Electronic Skin From NUS It's not every day you come across tech that could shake up multiple industries, but that's just what the National University of Singapore has cooked up with their latest brainchild—the eLuminator. This ain't your everyday wearable tech. We're talking a skin-like device that can both detect and show touch in real-time, no fiddly...

RiskScout Rides High on Funding, Tackles Financial Crime

A Fresh Injection to Combat Financial Crime Capital's flowing into RiskScout's coffers thanks to a new funding round, and it's not just about cash—it’s about gearing up for a battle against financial crime. The round was led by LiveOak Ventures, who aren't new to the block, alongside other players like Castle Creek Launchpad and Alloy Labs. After tripling their...